Weight-loss drug users drive demand for body contouring and skin tightening—a multi-billion-dollar shift.
The wave of GLP-1 adoption is rewriting the aesthetic practice playbook. As patients shed 20, 30, or 40 pounds on semaglutide or tirzepatide, they face a new problem: loose skin, stubborn pockets of fat, and sagging contours that diet and exercise alone won't fix. Aesthetic medicine is racing to capture this cohort.
Body contouring—RF microneedling, radiofrequency skin tightening, cryolipolysis, and combination protocols—is gaining traction faster than traditional injectables in this segment. Practices report that GLP-1 patients are less interested in preventive Botox and more interested in addressing structural changes. The opportunity is multi-billion-dollar and still early; most practices haven't yet built out the protocols or staffing to handle the volume.
GLP-1 patients prioritize body contouring over preventive injectables.
This reshuffles device and injectables economics. Practices that invested heavily in toxin and filler capacity may find themselves underutilized in this patient cohort, while those with RF, ultrasound, and body-contouring platforms are seeing utilization climb. The shift also favors practices with strong nurse-injector and clinical staff—body contouring requires more hands-on time and clinical judgment than a standard Botox appointment.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
